Loss of structures mediating connections between pyramidal cells (PyC), i.e., dendrites and spines, is a hallmark of aging and stress-related disorders, such as depression. These deficits occur in frontal cortex and hippocampus, regions critical for cognition, and are widely accepted as contributing to cognitive deficits. Cognitive deficits in depression and age-related disorders are not treated by current medications, highlighting an unmet need for novel procognitive and neurotrophic therapeutics. Efforts focused on excitatory-, brain-derived neurotrophic factor- or stress-related mechanisms have not yielded breakthroughs. In contrast, despite robust evidence for deficits in aging and depression, GABAergic inhibition has received less attention, since its augmentation impairs cognition without improving cellular connectivity.
Reduced GABAergic inhibition in aging and depression spans genes, cells, neurotransmitters and neurophysiological markers of inhibition. Of the multiple GABAergic cells and receptor subtypes, dendritic inhibition is mostly mediated by somatostatin-expressing GABAergic neurons (SST-neurons) and α5-containing GABA-A receptors (α5-GABAA-R), located in PyC dendrites (Fig. 1) [1]. Dendritic inhibition gates PyC excitatory input and regulates excitatory signal-to-noise ratio for optimal signal integration [2]. Consistent with loss of cell connection in aging and diseases, SST and α5-GABAA-R gene expressions decrease by 20–40% between ages 20 and 80 [3], and in depression [4]. Rodent genetic and environmental manipulations show that reducing SST-cell function induces anxiety- and depressive-like phenotypes, and cognitive deficits. Importantly, reducing α5-GABAA-R levels induces complex and bidirectional anxiety-like, memory and executive function changes, suggesting state-dependent contributions of α5-GABAA-R to cognitive functions [1, 4].
Reducing α5-GABAA-R function under conditions of hyper-GABAergic function has procognitive effects [1], but whether increasing α5-GABAA-R function under conditions of reduced GABAergic function was less characterized. Recently-developed molecules that preferentially activate α5-GABAA-Rs through positive allosteric modulation (α5-PAM) retain the anxiolytic effects of non-specific GABAA-R PAMs, such as benzodiazepines, and notably, show novel procognitive effects on spatial working memory deficits in aging and stress models following acute or chronic treatment, not observed with other GABAA-R PAMs, with little-to-no side effects in rodent models [5].
In addition to symptom relief, recent morphological studies showed that chronic α5-PAM treatment reverses age-related neuronal pathology (reduced spine density and dendritic complexity) in frontal cortex and hippocampus of aged mice, correlating with cognitive functions [6]. Studies also showed that a one-week treatment cessation maintained the neurotrophic, but not the procognitive effects, suggesting distinct and potentially synergistic α5-PAM effects of increasing α5-GABAA-R signaling and restoring neuronal morphology [6]. More recent studies report that these neurotrophic effects extend to chronic stress models. Chronic treatment with a racemic mixture with preferential α5-PAM activity reversed the stress-induced reduction in spine density in frontal cortex and hippocampus, correlating with cognitive functions [5].
Collectively, the procognitive and neurotrophic effects of α5-GABAA-R potentiation under conditions of reduced GABAergic function are novel and have symptomatic and disease-modifying therapeutic potential across brain disorders. The mechanisms of this unexpected neurotrophic effect may relate to neuronal “health”, through improved dendritic signal-to-noise ratio and restored capacity for optimal signal integration, although the reciprocal causal links between these structural, functional and behavioral events remain to be characterized.
References
Jacob TC. Neurobiology and therapeutic potential of alpha5-GABA type A receptors. Front Mol Neurosci. 2019;12:179.
Yao HK, Guet-McCreight A, Mazza F, Moradi Chameh H, Prevot TD, Griffiths JD, et al. Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits. Cell Rep. 2022;38:110232.
Lin CW, Chang LC, Ma T, Oh H, French B, Puralewski R, et al. Older molecular brain age in severe mental illness. Mol Psychiatry. 2021;26:3646–56.
Prevot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26:151–67.
Bernardo A, Lee P, Marcotte M, Mian MY, Rezvanian S, Sharmin D, et al. Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress. Neuropsychopharmacology. 2022;47:1608–19.
Prevot TD, Sumitomo A, Tomoda T, Knutson DE, Li G, Mondal P, et al. Reversal of age-related neuronal atrophy by alpha5-GABAA receptor positive allosteric modulation. Cereb Cortex. 2021;31:1395–408.
Funding
TP and ES are supported by the Weston Brain Institute, the American Foundation for Suicide Prevention, the Discovery Fund of the Center for Addiction and Mental Health. ES is supported by CIHR. ES and TP are listed inventors on patents covering the synthesis and use of GABAergic compounds. ES is Founder, acting CEO and CSO of DAMONA Pharmaceuticals, a biopharma dedicated to bringing novel GABAergic compounds to the clinic.
Author information
Authors and Affiliations
Contributions
TP and ES wrote the manuscript and prepared the figure.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Prevot, T.D., Sibille, E. Neurotrophic effects of potentiating gaba-mediated dendritic inhibition. Neuropsychopharmacol. 48, 213–214 (2023). https://doi.org/10.1038/s41386-022-01423-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-022-01423-0